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Abstract
Background: The increasing availability of different monoclonal antibodies (mAbs) opens the way to more specific
biologic therapy of cancer patients. However, despite the significant success of therapy in breast and ovarian
carcinomas with anti-HER2 mAbs as well as in non-Hodkin B cell lymphomas with anti-CD20 mAbs, certain B cell
malignancies such as B chronic lymphocytic leukaemia (B-CLL) respond poorly to anti-CD20 mAb, due to the low
surface expression of this molecule. Thus, new mAbs adapted to each types of tumour will help to develop
personalised mAb treatment. To this aim, we analyse the biological and therapeutic properties of three mAbs
directed against the CD5, CD71 or HLA-DR molecules highly expressed on B-CLL cells.
Results: The three mAbs, after purification and radiolabelling demonstrated high and specific binding capacity to
various human leukaemia target cells. Further in vitro analysis showed that mAb anti-CD5 induced neither growth
inhibition nor apoptosis, mAb anti-CD71 induced proliferation inhibition with no early sign of cell death and mAb
anti-HLA-DR induced specific cell aggregation, but without evidence of apoptosis. All three mAbs induced various
degrees of ADCC by NK cells, as well as phagocytosis by macrophages. Only the anti-HLA-DR mAb induced
complement mediated lysis. Coincubation of different pairs of mAbs did not significantly modify the in vitro results.
In contrast with these discrete and heterogeneous in vitro effects, in vivo the three mAbs demonstrated marked
anti-tumour efficacy and prolongation of mice survival in two models of SCID mice, grafted either intraperitoneally
or intravenously with the CD5 transfected JOK1-5.3 cells. This cell line was derived from a human hairy cell
leukaemia, a type of malignancy known to have very similar biological properties as the B-CLL, whose cells
constitutively express CD5. Interestingly, the combined injection of anti-CD5 with anti-HLA-DR or with anti-CD71
led to longer mouse survival, as compared to single mAb injection, up to complete inhibition of tumour growth in
100% mice treated with both anti-HLA-DR and anti-CD5.
Conclusions: Altogether these data suggest that the combined use of two mAbs, such as anti-HLA-DR and anti-
CD5, may significantly enhance their therapeutic potential.
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Background
Monoclonal antibodies (mAb) have become an integral
part in different treatments of lymphomas and leukae-
mias either as monotherapy or combined with che-
motherapy and other antibodies. MAbs can be used in
the form of unmodified antibodies or conjugated to
radioactive elements or toxins. Anti-CD20 rituximab
(Mabthera, Rituxan) has been extensively used and
approved for the treatment of patients with various
types of B-cell Non-Hodgkin Lymphoma (NHL). For the
treatment of B-cell Chronic Lymphocytic Leukaemia (B-
CLL), however, rituximab was found to be less success-
ful at least in part due to lower expression of CD20.
Thus, anti-CD52, alemtuzumab (Campath-1H) has been
used and approved, but other mAbs are needed for the
treatment of B-CLL. Many other mAbs directed against
cell surface molecules of lymphoid leukaemic cells
(CD4, CD19, CD22, CD23, CD30 CD40, CD74, CD80,
HLA-DR, CCR4) or molecules over-expressed in tumour
cells (CD71) are currently in clinical trial or in develop-
ment. In this study, we will focus on three monoclonal
antibodies directed against antigens strongly associated
with the B-cell lymphoid leukaemia phenotype [1,2]:
CD5, CD71 and HLA-DR.
CD5 is a marker of B-CLL, but is also expressed by
the B1a subset of IgM secreting B cells and by most
normal T cells. The biological role of this 65 kDa sur-
face receptor is not clearly defined, but it seems to par-
ticipate in immune tolerance as a negative regulator of
B and T lymphocytes antigen receptor signalling and
activation [3,4]. CD5 is overexpressed in B-CLL and
represents one important parameter required for the
diagnosis of B-CLL according to WHO criteria. It is also
expressed by prolymphocytic leukaemia and mantle cell
lymphoma, diseases with poor prognosis. The murine
IgG2a CD5 antibodies T101 and anti-Leu-1, either
unconjugated [5,6] or conjugated to toxins [7] or radioi-
sotopes [8], have been tested in patients for therapeutic
purpose. However, clinical benefits were limited or of
short in duration. More recently, it was demonstrated
that, in vitro, an anti-CD5 mAb can induce apoptosis of
B cells from some patients with CLL and that cross-
linking of CD5 on the surface of the cells was essential
for apoptosis induction [9,10].
CD71 is the major transferrin receptor, a 95 kDa
homodimeric (180kDa) type II transmembrane glycopro-
tein involved in the cellular uptake of iron and in the
regulation of cell growth [11]. CD71 is widely expressed
at low levels on normal cells and is overexpressed on
cells with a high proliferation rate. Interestingly, differ-
ent studies suggest that malignant tissues express CD71
at higher levels compared to their normal counterparts
[12]. Moreover, CLL and NHL have increasing expres-
sion of transferrin receptor correlating with the clinical
stage of the tumour [13]. Among several other mAbs,
the murine monoclonal IgA antibody 42/6, directed
against human CD71, demonstrated potent cytotoxic
effects on haematopoietic tumour cells [14]. Following
promising in vitro results, a phase I clinical trial was
conducted on 27 patients with various refractory and
advanced cancers of different origins [15]. The intrave-
nous infusions treatment showed little side effects.
Three patients, interestingly all of them with haemato-
poietic malignancies, demonstrated partial tumour
response. The short duration of the remissions observed
may be due to the rapid clearance of the IgA mAbs,
suggesting that antibodies of different isotypes, such as
chimeric and humanised mAbs could be more success-
ful. More recently, a chimeric CD71 antibody called
D2C has been reported to induce apoptosis and cell
cycle arrest in G1 phase in vitro [16].
The human leukocyte antigen (HLA)-DR is a class II
major histocompatibility complex (MHC) antigen which
is a major player involved in the presentation of pro-
cessed exogenous antigens to CD4+ helper T cells and
thus in the initiation of the immune response. HLA-DR
is expressed on several types of immune cells including
B cells, activated T lymphocytes, monocytes and dendri-
tic cells [17], and at a high level on B lymphoid leukae-
mias. Several studies have reported the ability of anti-
HLA-DR antibodies to induce direct cell death (DCD)
in vitro in either a caspase dependent or independent
way [18,19]. However, our own in vitro studies suggest
that DCD may be at least in part artefactual [20].
In vivo, the mechanism of tumour growth inhibition by
anti-HLA-DR mAb has not been entirely clarified. Two
anti-HLA-DR mAbs have been introduced in clinical
trials in treatment of NHL: Lym-1 and Hu1D10. The
radiolabelled murine IgG2a Lym-1 showed the first pro-
mising clinical results of radioimmunotherapy with
increased survival of patients with either NHL or B-CLL
[21]. Hu1D10 is a humanised antibody which, like Lym-
1, was reported to bind to a variant of the HLA-DRb
chain. Hu1D10 has been evaluated in patients with
relapsed or refractory indolent NHL where minimal
toxicity and early responses have been observed [22].
However, phase II clinical trials were disappointing.
Combination of Hu1D10 and rituximab has been
recently evaluated with modest therapeutic results [23].
In order to investigate the potential therapeutic activ-
ity against CD5+ B malignancies of new murine mono-
clonal antibodies directed against CD5, CD71 and HLA-
DR antigens, we evaluated their action, as single agents,
and in combination of two mAbs. The target cell bind-
ing capacity, anti-proliferative, and apoptotic effects of
the mAbs were evaluated in vitro on various lymphoma/
leukaemia cell lines, or B-CLL cells from patients.
In vivo, using two models of SCID mice i.p. or i.v.
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grafted with the human JOK1-5.3 cell line, we demon-
strated the capacity of the mAbs to prolong the animal
survival. Interestingly, a higher prolongation of the mice
survival was observed when two mAbs, instead of a sin-
gle one, were injected together.
Results
Binding of radio-iodinated mAbs to human leukaemia
and lymphoma cells
Purified 125I-radiolabelled mAbs showed specific binding
results of between 47 and 75% on cells expressing the
target antigen, non-specific binding being below 1% on
antigen negative cells (Table 1). Anti-CD5 mAb bound
only to the T-cell line Jurkat and to the leukaemia cell
line CD5+ JOK1-5.3, but not to the parental JOK1 cell
line nor to the B lymphoma cell lines. Both anti-HLA-
DR and rituximab, the latter taken as positive control,
showed specific binding to all B-cell lines. The anti-
CD71 mAb showed specific binding on all tested cell
lines. Similarly, specific binding was detected by flow
cytometry (data not shown).
In vitro effects of native single mAbs or pairs of mAbs
In order to determine the biological activities of the dif-
ferent mAbs, their potential effects on cell death after
24 hour incubation and on cell growth after 3-6 days
was evaluated using the vital dye alamar blue. MAb
anti-CD5 did not induce significant direct cell death of
JOK1-5.3, Daudi or Jurkat cell lines, at concentrations
up to 500 nM (75 μ g/ml) at 24 hours (Figure 1A and
data not shown), nor did the antibody induce prolifera-
tion inhibition at day 3-6 (Figure 1B). MAb anti-CD71
did not induce cell death at 24 hours but induced 25-
60% inhibition of JOK1 5.3 cell growth, observed after
3-6 days of culture (Figure 1B). Even more rapid and
effective inhibition of Daudi and Jurkat cell growth was
observed with anti-CD71 already at 48 hours using a
125I-IdUrd incorporation assay (60 and 25% of initial
values, respectively, data not shown), confirming that
anti-CD71 BA120 mAb can inhibit cell proliferation.
MAb anti-HLA-DR did not induce significant cell
death at 24 hours, as measured by alamar blue vital dye
(Figure 1A). However the antibody induced strong
aggregation of JOK1-5.3, Daudi and Raji, due to
homotypic adhesion as previously described [20,24,25].
Interestingly, this type of aggregation could lead to the
artefactual appearance of direct cell death, as deter-
mined by flow cytometry analysis of a minority of cells
after the exclusion of aggregated live cells [20]. Indeed,
examination of cytospin preparations of mAb treated
and 7AAD stained cells revealed only 2-5% of cell death
after anti-HLA-DR treatment, confirming the alamar
blue results (data not shown and [20]). The absence of
apoptosis induction by our anti HLA-DR mAb on Daudi
cells was confirmed by negative DNA laddering assay
(data not shown). Interestingly, the B-cell line, BL60.2,
which has a slightly lower surface expression of HLA-
DR than Daudi cells (0.25 × 106, molecules per cells, as
compared to 106, respectively) did not form any aggre-
gates and showed no evidence of apoptosis by annexin
V flow cytometry analysis after anti-HLA-DR mAb
treatment. In long term culture of JOK1-5.3 (3-6 days),
the anti-HLA-DR mAb induced only limited growth
inhibition (11 and 18% respectively) (Figure 1B and data
not shown). No growth inhibition of Daudi and Jurkat
cell lines at 48 hours was observed by 125I-IdUrd incor-
poration assay with this anti-HLA-DR antibody (data
not shown).
Thus, except for the known proliferation inhibition of
the anti-transferrin receptor (CD71) mAb, the 3 mAbs
analysed did not directly induce any significant cell
death or inhibition of proliferation in vitro (Figure 1A
and 5B).
In addition, coincubation of the target cell line JOK1-
5.3 in vitro with different pairs of the 3 native mAbs did
not induce detectable additional biological effects on the
target cells. For instance, addition of the anti-CD5 mAb
to anti-CD71 mAb did not induce any significant
increase of proliferation inhibition of the JOK1-5.3 cells,
as determined by 125I-IdUrd (Figure 1C). Similarly, the
addition of anti-CD5 or anti-CD71 to anti-HLA-DR
mAb did not modify the anti-HLA-DR mediated aggre-
gation of JOK1-5.3 cells nor did it produce any new
apoptosis induction properties (data not shown).
Antibody dependent cellular cytotoxicity (ADCC)
ADCC is thought to be one of the most important
mechanisms of action of therapeutic antibodies. In order
Table 1 Percentage binding of 125I labelled purified mAbs to different leukaemia/lymphoma cell lines
mAbs JOK1-5.3 JOK1 JURKAT DAUDI BL60.2
anti-CD5 61.6 (+/- 2.3) < 1% 75.0 (+/- 1.8) < 1% < 1%
anti-CD71 47.2 (+/- 5.5) n.d. 50.6 (+/- 6.5) 49.5 (+/- 2.6) 50.0 (+/- 2.6)
anti-HLA DR 56.1 (+/- 3.4) 50.7 (+/- 6.71) < 1% 56.2 (+/- 13.0) 63.4 (+/- 20.1)
anti-CD20 41.0 (+/- 3.4) 40.8 (+/- 2.5) > 1% 31.1 (+/- 5.6) 65.0 (+/- 6.2)
The percentage of binding of each 125I-labelled mAb to increasing numbers of each target cell lines was measured. Results are expressed as % of specific binding
extrapolated to an infinite number of target cells [44]
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to evaluate whether our anti-CD71, anti-HLA-DR and
anti-CD5 mAbs were active in the mediation of ADCC
by NK cells, CFSE labelled JOK1-5.3 were used as tar-
gets, after precoating with the different mAbs, followed
by incubation with purified NK cells during 4 hours.
Target cell death was next determined by 7AAD stain-
ing among CSFE labelled target cells by FACS analysis.
As shown in Figure 1D, all mAbs mediated significant
ADCC, with highest activity obtained by the anti-HLA-
DR mAb (78-88% lysis), followed by anti-CD5 (43-55%)
and anti-CD71 (33%) compared to 7-11% for control.
ADCC experiments performed were always including
controls with NK cells and target cells alone, or target
cells preincubated with mAbs, which showed less than
5% dead cells and therefore the specificity of the ADCC
reaction.
In separate experiments, using different donors of NK
cells, the induction of ADCC by coincubation with dif-
ferent pairs of mAbs, such as anti-CD5 and anti-HLA-
DR, anti-CD5 and anti CD71, or anti-CD71 and anti-
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Figure 1 In vitro biological activity of monoclonal anti-CD5, anti-CD71 and anti-HLA-DR antibodies. A, Induction of direct cell death or
apoptosis measured after 24 hours treatment of JOK1-5.3 cells with 10 μg/ml mAbs, using the vital dye alamar blue. Results are % dead cells
relative to control. CD5 = anti-CD5 mAb; DR = anti-HLA-DR mAb and CD71 = anti-CD71 mAb throughout. B, Effect on long term growth of
JOK1-5.3, measured after 3 or 6 days treatment with 10 μg/ml antibodies and alamar blue. Data are % of live cells relative to untreated cells
(CTRL) and are representative of at least 3 experiments. C, Percent proliferation of JOK1-5.3 cells, after incubation with single mAbs anti-CD5 or
anti CD71 or the two mAbs combination, at a identical total concentration of 75 μg/ml, for 24 or 72 hours, as compared to untreated control
cells, determined by incorporation of the radio-labelled thymidine analogue, 125I-Iododeoxyuridine. D, Induction of ADCC of JOK1-5.3 cells in
presence of 0.01, 0.1 or 1 μg/ml antibodies as indicated, using purified NK cells at a 10:1 effector to target ratio. E, Comparison of ADCC of JOK1-
5.3 cells in presence of single mAbs or pairs of anti-CD5+anti-HLA-DR, anti CD5+anti-CD71, or anti-CD71+anti-HLA-DR, at the total
concentrations of 2, 10 or 30 ng/ml, using NK cells at a 10:1 effector to target ratio. F, Induction of phagocytosis of B-CLL targets by in vitro
differentiated macrophages with 0.1 μg/ml antibodies. All data are representative of at least 3 experiments. G, Complement dependent cell lysis
of JOK1-5.3 cells with 10 μg/ml antibodies and 20% human serum.
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HLA-DR, was compared with the incubation of the dif-
ferent single mAbs at 3 identical total concentrations of
the single mAbs and the pair of mAbs. As shown in Fig-
ure 1E, the pairs of mAbs directed against different sur-
face markers did not induce additive or synergistic
ADCC effect.
Phagocytosis of mAb-opsonised B-CLL cells by human
macrophages
Phagocytosis by tissue macrophages is also a likely
important mechanism of action of therapeutic mAbs in
vivo [26]. Phagocytosis assays were performed by coin-
cubation of in vitro differentiated macrophages with B-
CLL targets in presence or absence of different mAbs,
followed by microscopic evaluation of stained phagocytic
cells [27]. The results of repeated experiments with the
different mAbs compared to rituximab, as positive con-
trol, show that both anti-CD5 and anti-HLA-DR antibo-
dies, but not anti-CD71, could mediate phagocytosis of
target cells by macrophages. Indeed a mean of 29-33%
phagocytosis was observed with these two mAbs (Figure
1E), compared to 37% with rituximab (data not shown).
In contrast anti-CD71 did not induce significant phago-
cytosis compared to the negative control (Figure 1E).
MAb induced complement-mediated lysis
Complement-mediated lysis (CDC) may play a role in
the mechanism of action of mAbs [28]. Since the induc-
tion of complement activation is dependent on both Ig
isotype and density and structure of the antigen recog-
nised by the mAb on the target cells surface, we tested
the capacity of our 3 mAbs to activate human comple-
ment. As shown in Figure 1C, the anti-HLA-DR mAb
induced a strong lysis of almost 80% of JOK1-5.3 cells,
while no significant lysis of the same cell line was
observed with either anti-CD5 or anti-CD71, even
though this cell line was positive for all 3 antigens.
In vivo anti-tumour efficacy of mAbs in SCID mice
To determine the in vivo antitumour activity of the dif-
ferent mAbs, we established two xenograft models of
the JOK1-5.3 cell line in mice, injected either i.p. or i.v.
In the first intraperitoneal model, therapy studies were
performed in SCID mice with i.p. grafted JOK1-5.3 leu-
kaemia. All mice treated with 2 i.p. injections of 0.5 mg
of mAb anti-CD5, CD20, CD71 or anti-HLA-DR, at 24
and 96 h after grafting, showed highly significant (p <
0.005) improvement of survival (Figure 2 and Table 2).
Median survival time was extended, from about 32 days
in controls, to 56 days after anti-CD71 treatment and
was not reached after the anti-HLA-DR treatment dur-
ing the four-month observation period. At study end,
absence of any sign of tumour at study end was
observed in 4 of 18 (22%) mice treated with anti-CD71
and in 11 of 18 mice (61%) treated with anti-HLA-DR
mAb. The anti-CD5 treatment resulted in 4 months sur-
vival without any sign of tumour in 9 of 21 mice (43%
mice), while tumour growth delay of about 14 days was
observed in the 12 other mice. Rituximab, injected as a
positive control in the same treatment regimen of the
JOK1-5.3 i.p. tumour model, led to a significant survival
advantage with complete response observed in 3 of 4
treated mice (Figure 2).
Ascites development was generally observed in
untreated mice at the same time as in mice treated with
control IgG1, requiring their sacrifice. In contrast, ascites
formation was observed only in a small minority of anti-
body treated mice (3.4%, 2/57 mice). However, in many
treated mice the tumours developed as s.c. inguinal and/
or intraperitoneal nodules (data not shown). The mice
were sacrificed when tumour load reached a volume of
1 cm3, and scored as dead. Injection of an irrelevant,
isotype matched control murine IgG1 had no significant
effect, as compared with PBS injected mice.
For the anti-CD5 murine IgG2a antibody, additional
control experiments were performed with mice bearing
the wild type JOK1 tumour that does not express mea-
surable amounts of CD5. This cell line was shown in
separate experiments to produce a median survival of 32
days when grafted i.p. in SCID mice, similar to JOK1-
5.3. As expected, treatment with the anti-CD5 mAb had
no effect on JOK1 wild type tumours.
In the second intravenous model, JOK1-5.3 cells were
inoculated i.v. into SCID mice. Mice received four i.v.
injections of 0.25 mg from the same murine anti-CD5,
CD71 and anti-HLA-DR mAbs or irrelevant control
IgG. All control mice had to be sacrificed because of
hind limb paralysis with median survival times of 18.5
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Figure 2 Antitumour efficacy of the single mAbs in the
intraperitoneal JOK1-5.3 model. Kaplan-Meier curves showing
survival fractions of SCID mice intraperitoneally grafted with JOK1-
5.3 cells and treated with 2 i.p. injections at day 1 and 4 of 0.5 mg
of mAbs anti-CD5, Anti-CD71, anti-HLA-DR and rituximab. Controls
were either untreated mice (PBS) or mice treated with an irrelevant
mouse IgG1 isotype. (All treated groups were significantly different
from the control groups p < 0.005). The study was performed twice.
Data are presented as cumulative percentage of both experiments.
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days. Mice that received mAb treatment had a signifi-
cant (p < 0.05) or highly significant (p < 0.005) prolon-
gation of survival when compared to mice that received
control antibody (Figure 3). Median survival time was
extended from 18.5 days in controls to 25 days, 29 days
and 45 days after anti-CD5, anti-CD71 and anti-HLA-
DR treatment, respectively. There was no statistically
significant difference between the survival curves using
anti-CD5 or anti-CD71. Despite survival prolongation,
all mAbs-treated mice eventually developed hind limb
paralysis.
Treatment with different combinations of two mAbs
improves the in vivo response
We next investigated whether combined treatment with
2 different antibodies could improve therapeutic
response in the same i.p. and i.v. tumour models. In the
i.p. model, the combined treatment with anti-HLA-DR
and anti-CD5 (Figure 4A and Table 2) led to a complete
response in 13 of 13 animals (100%), none of the mice
showing any sign of disease after 4 months. The combi-
nation of anti-CD5 and anti-CD71 also showed very
favourable results, with only 1 mouse out of 8 develop-
ing a subcutaneous tumour, while 7 animals (88%) were
apparently cured (Figure 4B and Table 2). The results
from both of these treatment combinations, anti-HLA-
DR/anti-CD5 and anti-CD5/anti-CD71 yielded a signifi-
cant increase in survival compared with treatment by
the individual mAbs alone, using the same quantity as
the total of the combined mAbs injections. The combi-
nation of anti-HLA-DR and CD71 mAb resulted in
tumour growth inhibition and apparent cure in 7 of 13
mice (54%). However, this result was not significantly
different from that obtained with the anti-HLA-DR
mAb used alone (Figure 4C).
In the i.v. model of JOK1-5.3 bearing SCID mice,
treatment with the three possible combinations of mur-
ine antibodies resulted in prolongation of mice survival,
as compared with placebo-treated controls (Figure 5).
The combination of anti-CD5 and anti-HLA-DR con-
firmed the high efficacy of this combination already
observed in the i.p. model, with complete response
observed in all animals (12/12, 100%) and none of the
mice showing any sign of disease after 10 months
(Figure 5). As shown in Table 3, the median survival
times of animals treated with anti-HLA-DR plus anti-
CD5 mAbs was more than 300 days, representing an
apparent cure, while treatment with anti-CD71 plus
anti-HLA-DR mAbs led to a 52 days median survival
(52-53) and 6/12 mice (50%) cured. Treatment with
anti-CD71 plus anti-CD5 mAbs gave a slightly lower
median survival of 45 days (37-82) and only 2/12 (17%)
of mice cured, but this has to be compared with a med-
ian survival of only 18.5 days (19-20) and no cure for
PBS treated mice.
Discussion
This report was aimed at analysing the activities of three
new mAbs, directed against different cell surface mole-
cules preferentially expressed by B-CLL and other hae-
matopoietic tumours: CD5, the transferrin receptor or a
Table 2 Comparison of antitumour efficacy of single and combined mAbs in the intraperitoneal tumour model
Injected mAbs Medium survival in days N° of tumour free animal at day 120 (%)
Anti-HLA-DR > 120* 11/18 (61%)
Anti-CD5 81* 9/21 (43%)
Anti-CD71 56* 4/18 (22%)
Anti-HLA-DR + anti-CD5 > 120** 13/13 (100%)
Anti-CD71 +anti-CD5 > 120** 7/8 (88%)
Anti-CD71 + anti-HLA-DR > 120 7/13 (54%)
Untreated animals 32 1/47 (2%)
*significantly different from irrelevant IgG injected control mice (p < 0.005)
**significantly different from both single antibody treatments (p < 0.05)
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Figure 3 Antitumour efficacy of the single mAbs in the
intravenous JOK1-5.3 model. Kaplan-Meier curves showing
survival fractions of SCID mice grafted by i.v. injection via the tail
vein of 10 × 106 JOK1-5.3 cells and treated with i.v. injections of
either mAb anti-CD5, anti-CD71 or anti-HLA-DR (0.25 mg on days
+3, +5, +7 and +11) or irrelevant mouse IgG1 isotype. All treated
groups are significantly different from the control groups p < 0.005).
The study was performed twice. Data are presented as cumulative
percentage of both experiments.
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class II MHC molecule. We started our evaluation of
the mAbs by an in vitro analysis of their biological
effect, without or with effector cells, on different target
leukaemia/lymphoma cell lines, expressing the relevant
molecules. Except for some proliferation inhibition by
anti-CD71, none of the antibodies showed significant
direct cell death induction at 24-48 hours. In contrast,
all antibodies showed immune mediated activities, such
as CDC (anti-HLA-DR), phagocytosis (anti-CD5 and
anti-HLA-DR) and ADCC (all 3 mAbs with different
efficiencies). Interestingly, in vitro, the incubation of tar-
get cells with different pairs of mAbs did not induce any
significant superior anti-tumour effect.
We then tested the MAbs in a first in vivo model,
consisting of the direct injection of both the tumour
cells and the antibodies, after 24 hours, in the peritoneal
cavity of immunodeficient SCID mice. Encouraged by
the significant specific anti-tumour effect of the three
mAbs, we moved to a more relevant tumour model with
target cells injected in the tail vein of the same type of
mice, followed by the systemic injections of the mAbs
by the same route. The systemic injection of the mAbs
confirmed and extended the encouraging anti-tumour
effects obtained in the peritoneal cavity model. Then,
we moved to the second part of our experimental ther-
apy analysis, which demonstrates that the coinjection of
different pairs of two mAbs in the same animals can
give significant improvements of anti-tumour effect as
compared to single mAb injection.
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Figure 4 Increased antitumour efficacy of the injection of two mAbs combination in the intraperitoneal JOK1-5.3 model. Kaplan-Meier
curves showing survival fractions of SCID mice intraperitoneally grafted with JOK1-5.3 and treated with two i.p. injections of different
combinations of two mAbs (0.25 mg of each mAb) at day 1 and 4: A, combination of anti-HLA-DR and anti-CD5, B, combination of anti-CD71
and anti-CD5 or C, combination of anti-HLA-DR and anti-CD71 mAbs. Combination treatments were compared with two i.p. injections of 0.5 mg
from only one mAb at day 1 and 4, or PBS injected control mice. The study was performed twice. Data are presented as cumulative percentage
of both experiments.
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Figure 5 Increased antitumour efficacy of the injection of two
mAbs combination in the intravenous JOK1-5.3 model. Kaplan-
Meier curves showing survival fractions of SCID mice intravenously
grafted with JOK1-5.3 and treated by i.v. injections of different
combinations of two mAbs (0.25 mg on day 3, 5, 7 and 11):
combination of anti-HLA-DR plus anti-CD5, anti-HLA-DR plus anti-
CD71, or anti-CD71 plus anti-CD5 mAbs. Controls were mice
injected with PBS. The study was performed twice. Data are
presented as cumulative percentage of both experiments.
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The fact that our three mAbs had efficient anti-
tumour effect in vivo, in both our local i.p. and systemic
i.v. models, as well as mostly immune mediated effects
in vitro, strongly suggests that our antibodies are acting
in vivo with the help of autologous biological mediators,
such as effector cells and/or complement. In addition a
direct antiproliferative effect of anti-CD71 may play a
role. However, it remains difficult to determine which of
the different effector mechanisms for each mAb is play-
ing the most important role in the induction of the
observed anti-tumour effect. In this context, it is worth
mentioning that even for the most successful anti-cancer
therapeutic mAbs broadly used in the clinic, such as
anti-CD20, anti-HER2 or anti-EGF receptor, the exact
mechanism of anti-tumour activity has not yet been
entirely elucidated. For anti-EGF receptor mAbs, it is
claimed that they block the accessibility to the different
EGFR ligands, but for anti-HER2, which is an orphan
receptor without ligand, this type of mechanism does
not apply.
A few years ago, there was almost a consensus that
ADCC by NK cells and phagocytosis by macrophages
were indeed the most important mechanisms of mAb
cancer therapy. This opinion was initially based on
experimental results showing that in nude mice
knocked-out for Fcg receptor, the anti-HER2 and anti-
CD20 mAbs were inefficient to treat human tumours
expressing the relevant target antigens [29], and second,
on the clinical observations of a correlation between
FcgR3A genetic polymorphisms and response to mAb
therapy [30,31].
However, recent experimental results showing that the
F(ab’)2 fragments of anti-EGFR and anti-HER2 mAbs
could significantly inhibit the growth of pancreatic carci-
noma xenografts in nude mice, clearly demonstrate that
at least part of the anti-tumour effect is not ADCC
mediated and must be due to binding of the F(ab’)2 frag-
ments to the sensitive HER1 and HER2 receptors [32].
Furthermore, the fact that the most successful mAbs,
clinically accepted for cancer therapy, are directed
against sensitive surface receptors (EGFR and HER2) or
calcium pump like structure (CD20), suggests that at
least part of the anti-tumour effect of mAbs is induced
by their capacity to activate or block a pathway of inter-
nal signalling, leading to inhibition of tumour cell prolif-
eration. In relation to our tumour model system, it is
interesting to note that the CD5 molecule was pre-
viously shown to act as negative regulator of T or B
cells [33]. However, the absence of additive effect of the
coincubation of two mAbs on target cells in vitro, is not
in favour of the hypothesis that the superiority of our
two mAbs in vivo treatment would be due to a coopera-
tive inhibitory pathway.
Concerning the role of complement, its activation at
the tumour site should help control tumour through
C3b opsonisation of tumour cells, or by the release of
C3a or C5a anaphylatoxins, which should attract
immune cells, increase the vasodilatation and permeabil-
ity of tumour vessels and thus the accessibility of more
antibody molecules. However, those who think that
tumour growth is entirely dependent on vascularisation
[34] may be against the induction of complement activa-
tion. Similarly, the activation of complement by anti-
CD20 has been demonstrated, but the possible positive
or negative role of complement in tumour therapy is
still the subject of debate [28].
Regarding the question of in vitro cytotoxicity of anti-
HLA-DR antibody, in the course of the in vitro study,
we made the following original observation. Anti-HLA-
DR mAbs were known to induce cell aggregation,
through homotypic adhesion, of cell lines expressing
this antigen and were reported, on the basis of flow
cytometry analysis after annexin V, or propidium iodide
staining, to induce up to 80% cell death [35]. However,
after reproducing these results with our own anti-HLA-
DR mAb on Daudi and JOK1-5.3 cells, we found that
these high cytotoxicity results were likely to be artefac-
tual due to the exclusion in the analysis of live aggre-
gated cells, resulting in the detection of apoptosis on a
minority of cells remaining in single cell suspension. In
contrast, when the bulk of antibody treated cells were
tested without preselection on cytospin preparations, by
7AAD staining, we found only a minority of dead cells
[20]. Interestingly the B-cell line, BL60.2, which was
found to express 4 times less HLA-DR molecules than
Daudi cells and does not present any aggregation upon
treatment with anti-HLA-DR mAb did not show either
any evidence of mAb induced cytoxicity, when tested by
annexin V staining and conventional flow cytometry
analysis (PAA unpublished observations). This repre-
sents an additional argument in favour of our interpre-
tation that the flow cytometry evidences of anti-HLA-
DR induction of direct cytotoxicity are artefactual.
Table 3 Comparison of antitumour efficacy of single and
combined mAbs in the intravenous tumour model
Injected mAbs Median survival in days N° of tumour
free animal at
day 300 (%)
Anti-HLA-DR 45* 0/10 (0%)
Anti-CD5 25* 0/10 (0%)
Anti-CD71 29* 0/6 (0%)
Anti-HLA-DR + anti-CD5 > 300** 12/12 (100%)
Anti-CD71 + anti-CD5 45** 2/12 (17%)
Anti-CD71 + anti-HLA-DR 52** 6/12 (50%)
Untreated animals 18.5 0/36 (0%)
*significantly different from irrelevant IgG injected control mice (p < 0.005)
**significantly different from both single antibody treatments (p < 0.05)
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The simultaneous attack on tumour cells by the coin-
jection of two mAbs represents a promising new thera-
peutic strategy, whose mechanism of action is far from
being understood. Among the few examples in the lit-
erature, the coinjection of anti-CD20 and anti-CD22
mAbs has already been clinically evaluated in the treat-
ment of non-Hodgkin lymphomas. However, despite the
description of some durable complete tumour responses,
the advantage of adding the humanised anti-CD22, epra-
tuzumab to the standard treatment with anti-CD20
rituximab, has not yet been convincingly demonstrated
[36]. Similarly, several early clinical trials testing the
coinjection of alemtuzumab with rituximab were
reported with good tolerance, but not yet the demon-
stration of a clear clinical benefit [37,38].
Experimentally, two other coinjections of mAbs have
been reported to induce synergistic anti-tumour effect.
The first associated the injection of two mAbs directed
against EGF and VEGF receptors, which were not
expressed by the same target cells. Thus, the synergistic
effect was attributed to a double action of the anti-
EGFR directly on tumour cells and of the anti-VEGFR
on the tumour vascular component [39]. The second
consisted in the coinjection of mAbs directed against
two receptors of the HER family, matuzumab anti-EGFR
(HER1) and trastuzumab, anti HER2. These two mAbs
showed a clear synergistic therapeutic activity, as com-
pared to single mAb injection, against two human pan-
creatic carcinoma xenografts, expressing the two
receptors [40]. Here again, the mechanism of the syner-
gistic effect was not fully understood, but was likely due
to inhibition of the dimerisation of the two receptors,
which is known to represent a central activation signal.
Furthermore, in this case, the anti-tumour synergism
was not due only to an increase of NK cells recruitment,
since the anti tumour synergism was confirmed by the
use of F(ab’)2 fragments from the two mAbs [32].
Conclusions
We have demonstrated here the higher anti-tumour
effect of the combined injection of two mAbs, as com-
pared to single mAb injection. The fact that the com-
bined mAbs anti-tumour effect was not observed in
vitro, but only in vivo, strongly suggest that the thera-
peutic advantage obtained with different pairs of mAbs
is due to multiple antibody induced effector mechan-
isms, such as ADCC, phagocytosis and/or CDC. In
some mAbs combination, we cannot rule out a simple
additive effect due to the involvement of two mAbs
reacting with independent antigens expressed by the
tumour cells, but in the case of the coinjection of anti-
HLA-DR and anti-CD5, or anti-CD71 and anti-CD5
mAbs, the clear advantage of same amounts of mixed
mAbs over single mAb, as demonstrated in the i.p.
model, are definitely in favour of a synergistic anti-
tumour effect. This synergism associated with different
mechanisms of action of the antibodies, is likely to be
responsible for the complete inhibition of tumour
growth after i.v. coinjection of anti-HLA-DR and anti-
CD5 mAbs and suggest that the systemic injection of
such pairs of mAbs represents a promising therapy
strategy. Mouse-human chimerisation or humanisation
of the mAbs, as well as synthesis of bispecific antibodies,
with binding sites selected from the best pairs of mAbs,
will have a good chance to further improve the observed
therapeutic efficiency.
Methods
Cells and Reagents
The human Hairy Cell Leukaemia (HCL) JOK1 (CD5-,
CD71+, HLA-DR+, CD20+) was stably transfected with
pLNCX vector carrying human CD5 cDNA. Briefly, sub-
lclone JOK1-5.3 stably expressing human CD5+ on the
cell surface was selected by limiting dilution and
expanded in vitro. The cells stably maintained CD5
expression, as determined by standard immunopheno-
typing and FACS analysis (MFI22) to levels similar to
that observed in B-CLL for up to 6 months continuous
culture ([41] and Le Ster K et al., manuscript in prepara-
tion). We verified that JOK1-5.3 had the following phe-
notype: CD5+, CD71+ HLA-DR+ and CD20+. The
Human Burkitt’s lymphoma cell lines Daudi (American
Type Culture Collection, ATCC) and BL60.2 [42],
(kindly provided by Dr Stephan Mathas, Max-Delbrück-
Center for Molecular Medicine, Berlin, Germany) are
CD5-, CD71+, HLA-DR+, CD20+, while the Human
Jurkat T-cell leukaemia line (ATCC) is CD5+, CD71+,
CD20- and HLA-DR-. All cells were grown in
RPMI1640 medium (Gibco, Invitrogen) supplemented
with 10% fetal calf serum, 2 mM l-glutamine, 150 μg/ml
penicillin-streptomycin (Gibco, Paisley, Scotland).
Heparinised peripheral blood was obtained after
informed consent from patients with B-CLL at diagno-
sis. All patients were diagnosed by routine immunophe-
notypic, morphologic, and clinical criteria. In all cases,
double staining with CD19 and sIg was performed,
allowing us to establish monoclonality and to determine
the percentage of neoplastic versus normal B cells pre-
sent in the sample. The cells were separated on a Ficoll
Hypaque gradient (Seromed, Berlin, Germany).
The murine monoclonal antibodies anti-CD5 (O490,
IgG2a), anti-CD71 (BA120G, IgG1) and anti-HLA-DR
(BK267W, IgG1) were developed by the laboratory of L.
Boumsell (INSERM U567, France) and kindly produced
and purified by the MAT Biopharma laboratory (MAT
Biopharma Evry, France). BK267 was shown to recog-
nise HLA-DR molecules by tissue distribution and Wes-
tern blot. A mouse anti-CEA mAb of IgG1 subclass was
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used as control immunoglobulin for IgG1 antibodies.
The chimeric anti-CD20 monoclonal antibody rituximab
and the humanised anti-CD52 antibody alemtuzumab
(Campath-1H) were obtained from Roche Pharma,
Basel, Switzerland and Bayer Schering Pharma, Berlin,
Germany respectively.
Radiolabelling of mAbs and binding measurements
The radiolabelling of mAbs with 125I was performed by
the Chloramine T method using 37MBq/mg of protein
(1mCi/mg) [43] and purified on Dowex ion exchange col-
umn. The radiochemical purity of the different labellings
was controlled by Instant Thin Layer Chromatography
using 85% MeOH buffer as mobile phase and/or by
HPLC using size exclusion column BIOSep SEC S3000.
To assess the antigen binding specificity of the mono-
clonal antibodies to the different cell lines, fixed
amounts of 125I-labeled-mAb (6ng~7500 cpm) were
incubated with various numbers of cells (2-10 × 106
cells) in 100 μl of PBS (Phosphate Buffer Saline 0.16M,
pH7.4), 2% FCS for 2 hours at 4°C. Non-specific binding
was determined by specific binding inhibition with an
excess (100 μg) of unlabelled antibody. Cells were then
washed with ice-cold PBS/FCS to remove unbound
mAbs and cell-bound activity was measured on a g-
counter. Binding results are expressed as percent of spe-
cific binding in comparison with the 100% of initial
incubated activity and extrapolated to an infinite quan-
tity of antigen as determined by Lindmo et al. [44].
Direct cell death and complement-dependent cytotoxicity
Complement dependent cytotoxicity (CDC) and direct
cell death were determined using the alamar blue vital
dye (Biosource International, Camarillo, CA, USA)
essentially as described [45]. Briefly, 20 000 cells/well
were plated in 100 μL in quadruplicate in 96-well plates
in the presence of 10 μg/mL of mAbs in the presence
(CDC) or absence (direct cell death) of 20% pooled
human serum from normal donors. After 24h of incuba-
tion at 37°C, the total volume was brought to 300 μL in
medium containing 1/10 volume of alamar blue solution
(Biosource International, Camarillo, CA, USA). Incuba-
tion was carried on 8-16 hours at 37°C and the plates
were read in a fluorimeter (Genios, Tecan, Männedorf,
Switzerland) with excitation at 530 nm and emission at
590 nm. Cell death was calculated as percentage
decrease in live cells after subtracting background fluor-
escence given by medium alone.
Inhibition of cell growth
10.000 JOK1-5.3 cells/well were plated in 96 well plates
in presence or absence of 10 μg/ml antibodies. After 3
to 6 days at 37°C 5% CO2, 1/10 volume alamar blue
solution was added and incubation continued for further
8 hours. Plates were read in a fluorimeter (Genios,
Tecan) with excitation at 530 nm and emission at 590
nm. Inhibition of cell growth was calculated as percen-
tage decrease in live cells relative to untreated controls,
after subtracting background fluorescence.
Another test of the effects of mAbs on cell prolifera-
tion was made by measuring the incorporation of the
radio-labelled thymidine analogue 125I-Iododeoxyuridine
(125I-IdUrd). In brief, after the different times of incuba-
tion with individual Mabs or pair of mAbs at a final
total concentration of 75 mg/ml of mAbs the target
cells, JOK1-5.3 (2’500 cells per well of 96 wells culture
plates) were further incubated for 4 hours at 37°C with
5kBq of 125 I-IdUrd. After thorough washing, cell-pellet
associated radioactivity was measured, using a g-counter
and cell proliferation inhibition was calculated on a
titration curve established with known concentrations of
untreated control cells. All tests were performed in tri-
plicate and repeated at least 2 times.
Phagocytosis
Phagocytosis was performed, as described previously, by
differentiating monocytes to macrophages in vitro by 7
day culture in presence of rhM-CSF [27]. Briefly, CD14+
monocytes were plated n 8-well Lab Tek chamber slides
(Cebio, Milan, Italy) at 200 000 cells/well and allowed to
differentiate as above. B-CLL target cells were incubated
in presence or absence of antibody and then added to
macrophages at a 1:1 ratio in RPMI 1640/10% FBS. After
2 h at 37°C, cells were fixed and stained with Diff Quick
and percentage phagocytosis was measured by counting
macrophages having engulfed one or more B-CLL.
ADCC
NK cells were positively selected from Ficoll-Isopaque
purified PBMC using RosetteSep Human NK cell
enrichment cocktail as recommended by the manufac-
turer. JOK1.5.3 or other target cells (JOK1 wild type,
Jurkat or normal PBL) were first labelled for 10 min at
37°C in the dark, with CSFE (CellTrace CFSE Cell Pro-
liferation Kit, C34554, Invitrogen, Paiseley, UK).
Labelled target cells were aliquoted into a 96 well cul-
ture plate (25 000 per 50 μL) and appropriate dilution
of chimeric antibodies or control human Ig1 was also
added to the plate. Plates were incubated for 20min at
4°C. Next, NK cells were added to the wells at a 10:1
ratio. Plates were incubated for 4 hr at 37°C. After incu-
bation each well was transferred into a 5ml tube and
7AAD was added to each tube (Invitrogen). After a final
15min incubation at room temperature in the dark,
tubes were analysed by flow cytometry. Target cells
were gated by their CFSE labelling, while the percentage
of dead cells among target cells was identified by 7AAD
labelling.
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In vivo studies
SCID CB-17 mice, aged 6-8 weeks, were purchased from
the Charles River Breeding Laboratories (Wilmington,
MA, USA mice used in the i.p. model), or Harlan
(Boxmeer, Netherlands, mice in the i.v. model). Mice
were kept under specific pathogen-free conditions in a
separate facility using autoclaved cages of micro-isolator
units and fed with irradiated solid food and sterilised
water. All protocols were approved by the Institutional
Ethics Committee for Animal Experimentation of Brit-
tany (authorization b-2005-SL-04) and Swiss legislation
(authorization VD 2013).
For the intraperitoneal model, 5 × 106 JOK1-5.3 cells
in exponential growth were inoculated by 2 bilateral
intra-peritoneal injections. Treatment consisted of 2 i.p.
injections of 0.5mg of each mAb 24h and 92h after
grafting. Controls mice were injected with PBS or an
isotype matched irrelevant IgG1. For experiments invol-
ving the IgG2a anti-CD5 antibody, control mice grafted
with JOK1-5.3 (CD5+) were injected with PBS, and, in a
parallel experiment, other control mice were grafted
with wild type JOK1 cells (CD5-) and tested with anti-
CD5 antibody treatment and compared with PBS injec-
tion. Animals were monitored three times per week for
tumour appearance, bodyweight measurement and signs
of disease (ascites, cachexia). Subcutaneous tumour
volume was measured with the formula (length × width
× 2/3 width)/2. Experiments using combination treat-
ments consisted of 2 injections i.p. of 0.25 mg of each
mAb (0.5 mg total) 24 h and 96h after grafting. Combi-
nation treatments were compared to single agent treat-
ment consisting of 2 injections of 0.5 mg each from the
same mAb at 24 h and 96 h.
For the intravenous model, 10 × 106 JOK1-5.3 cells
suspended in 0.1 ml PBS were injected i.v. into the tail
vein. Mice were randomly divided into groups and
injected i.v. with 0.25 mg of either irrelevant IgG1 or
mAb on days 3, 5, 7, and 11. In combination experi-
ments 0.25 mg of each mAb were coinjected i.v.. Mice
were monitored daily for the presence of hind-leg
paralysis and in that case sacrificed and scored as dead.
Animal survival analysis
Kaplan-Meier plots and statistical analysis were per-
formed using the GraphPad Prism 5 software and the
log-rank (Mantel-Cox) test. Differences between curves
were considered significant if p value was < 0.05, and
highly significant if p < 0.005.
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